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Background/aim: The aim of the study was to compare the luteal estradiol patch/GnRH antagonists priming protocol (LPP) with the
standard GnRH antagonist protocol in poor ovarian responders (PORs) in terms of the outcomes of in vitro fertilization (IVF) treatment
Materials and methods: IVF outcomes of 265 cycles in 265 patients (106 in the LPP group, 159 in the standard GnRH antagonist group)
were evaluated retrospectively.
Results: Mean length of stimulation (11.4 ± 2.7 vs. 10.0 ± 2.7 days; P < 0.05) and the total gonadotropin dose (3403 ± 1060 vs. 2984
± 1112) used were significantly greater in the LPP group than in the standard GnRH antagonist protocol group. The mean number of
oocytes retrieved (3.5 ± 2.6 vs. 3.7 ± 2.8), the number of mature oocytes (2.8 ± 2.2 vs. 2.6 ± 2.2), fertilization rates (65% vs. 62%), the
number of embryos transferred (1.6 ± 0.6 vs. 1.7 ± 0.6), and implantation rates (16% vs. 13%) were similar. The cancellation rate did
not significantly differ between the groups (9.4% vs. 13.2%). There were no significant differences in the clinical pregnancy (11.3% vs.
13.2%) or live birth rates per patient (3.8% vs. 9.4%) and clinical pregnancy (18.8% vs. 22.6%) or live birth rates per embryo transfer
(6.3% vs. 12.9%) between the groups.
Conclusion: LPP does not improve IVF outcomes when compared with the standard GnRH antagonist protocol in PORs.
Key words: In vitro fertilization, poor ovarian response, GnRH antagonists, estradiol

1. Introduction
Poor ovarian responders (PORs) are the most compelling
infertile population subgroup in assisted reproduction,
with a prevalence ranging from 9% to 24% (1). In PORs,
total number of growing follicles, retrieved oocytes,
and transferred embryos; peak estradiol levels; and
implantation and pregnancy rates are all lower whereas
cycle cancellation rates are higher than they are in women
who respond normally to ovarian hyperstimulation
(COH) (2,3).
Poor ovarian response to COH is a result of
decreased numbers of mature oocytes due to follicular
asynchronization as well as low ovarian reserve (4,5).
In PORs, a rise in FSH in the late luteal phase induces
development of sensitive and larger antral follicles and
causes asynchronization among follicle diameters. As
a result, the number of follicles ready for recruitment
and the number of retrieved oocytes decrease (6,7). In
this patient group, various protocols have been used to
increase success rates, but none of these has prevailed
* Correspondence: firatmutlu78@hotmail.com
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(8,9). Dragisic et al. were the first who used the luteal
estradiol patch/GnRH antagonists priming protocol (LPP)
in an attempt to overcome early FSH rise in the luteal
phase without suppressing ovarian functions (10). In this
protocol, simultaneous administration of a transdermal
estradiol patch and GnRH antagonist helps to achieve
dual suppression of FSH and subsequently gonadotropin
stimulation with addition of flexible antagonist is started
in the cycle (10). In some studies, LPP has been compared
with well-known protocols (GnRH antagonist and
microdose flare-up) (6,7,10–15). A recent meta-analysis
shows that LPP has significantly higher clinical pregnancy
rates when compared with other protocols. However,
the results were limited by uncertain definitions of poor
responders in the included studies (16).
Our search of the current literature revealed no trials
comparing the standard GnRH antagonist protocol with
the luteal estradiol patch/GnRH antagonists priming
protocol. The aim of our study was to examine whether
adding luteal estradiol and GnRH antagonist pretreatment

MUTLU et al. / Turk J Med Sci
to GnRH antagonist protocols can improve in vitro
fertilization (IVF) outcomes in PORs.
2. Materials and methods
A retrospective review of records between May 2014 and
September 2015 was performed at our clinic. Two hundred
and sixty-five PORs according to the European Society of
Human Reproduction and Embryology (ESHRE) Bologna
criteria were included (17). Women were classified as
PORs if they met at least two of the following three criteria:
(i) advanced maternal age (≥40) or any other risk factor
for poor ovarian response; (ii) a previous poor ovarian
response (cycles cancelled or ≤3 oocytes retrieved with a
conventional protocol); (iii) an abnormal ovarian reserve
test (ORT) (antral follicle count <5–7 follicles or antiMüllerian hormone (AMH) <0.5–1.1 ng/mL). Women
who had two episodes of poor ovarian response after
maximal stimulation in the absence of advanced maternal
age or an abnormal ORT were also defined as poor
responders (fourth item of the Bologna criteria). Patients
aged ≤25 and ≥43 were excluded. The institutional review
board approved the study.
Patients in the LPP group started using one 0.1 mg/
day transdermal estradiol patch (Climara forte, Bayer,
İstanbul, Turkey) 7 days after ovulation, which was proved
by transvaginal ultrasonography (TVU), and changed
the patch every other day three times. The last estradiol
patch was removed on the second day of menses. Even
if menstrual bleeding did not start, the last estradiol
patch stayed on for no longer than 1 week. Following the
day on which the first patch was applied, 0.25 mg/day
subcutaneous GnRH antagonist cetrorelix (Cetrotide;
Merck–Serono, İstanbul, Turkey) was started and applied
for 3 days. The patients on the GnRH antagonist protocol
did not receive any hormonal pretreatment during the
luteal period.
In both groups, ovarian stimulation with 150 IU
recombinant FSH (Gonal-F; Merck Serono, İstanbul,
Turkey) and 150 IU hMG (Merional; IBSA, Turkey)
was started on the second day of menses. Monitoring of
follicular development and gonadotropin dose adjustments
were performed with serial ultrasound and levels of serum
E2. Cetrorelix (Cetrotide; Merck Serono) was started 0.25
mg/day subcutaneously when the leading follicle was >13
mm or E2 >300 pg/mL and was continued through the
day of human chorionic gonadotropin (hCG) injection.
Cycle cancellations were performed due to lack of ovarian
response (when there were no follicular recruitment and/
or peak E2<100 pg/mL despite adequate gonadotropin).
When one or more follicles were 17 mm or more in mean
diameter, hCG (Ovitrelle 250 µg; Merck Serono) was given
for final oocyte maturation. Endometrial thickness was
measured by TVU on the day of hCG administration and
recorded.

TVU-guided oocyte retrieval was performed 35 h after
hCG administration. ICSI was carried out in all cases. One
to three embryos were transferred under ultrasonographic
guidance 48–72 h after oocyte pick-up, depending on the
quality and number of embryos. For luteal support, 90
mg daily intravaginal progesterone gel (8% Crinone gel;
Merck Serono) and 4 mg daily oral estradiol hemihydrate
(Estrofem 2 mg, Novo Nordisk, İstanbul, Turkey) were
administered starting on the day after oocyte pick-up
and, if the pregnancy test performed 12 days after embryo
transfer (ET) was positive, continued until 9 weeks of
gestation.
Pregnancy was tested by measuring serum βhCG
level 12 days after ET and intrauterine pregnancy was
confirmed by TVU examination 2 weeks after a positive
pregnancy test. Clinical pregnancy was defined as a
pregnancy confirmed by ultrasound visualization of the
gestational sac between the 5th and 6th weeks of gestation.
Implantation rate was defined by the number of gestational
sacs on ultrasound divided by the number of embryos
transferred. Live birth rate was defined as delivery of a
viable baby after 24 weeks of gestation.
Primary outcomes were number of oocytes retrieved
and live birth rate. The secondary outcome was cycle
cancellation rate.
All statistical analyses were performed using SPSS
version 20 (Chicago, IL, USA). Student’s t-test was used
for continuous variables, and the chi-square test was used
for categorical variables. P values <0.05 were considered
statistically significant.
3. Results
A total of 265 patients were included in the study;
106 women used the LPP and 159 women were given
the standard GnRH antagonist protocol. The baseline
characteristics of patients are presented in Table 1. The
groups were similar with respect to age, body mass index
(BMI), basal FSH, duration of infertility, basal antral
follicle count, and number of prior IVF attempts.
The cycle characteristics and outcomes are presented
in Table 2. Mean length of stimulation (11.4 ± 2.7 vs. 10.0 ±
2.7 days; P = 0.01) and the total gonadotropin dose (3403.7
± 1060.6 vs. 2984.4 ± 1112.1 IU; P < 0.05) used were
significantly higher in the LPP group than in the standard
GnRH antagonist protocol group. The mean number
of oocytes retrieved (3.5 ± 2.6 vs. 3.7 ± 2.8), number of
mature oocytes (2.8 ± 2.2 vs. 2.6 ± 2.2), fertilization rates
(65% vs. 62%), number of embryos transferred (1.6 ±
0.6 vs. 1.7 ± 0.6), and implantation rates (16% vs. 13%)
were similar. The cancellation rates were not significantly
different between the groups (9.4% vs. 13.2%). There were
no significant differences in the clinical pregnancy (11.3%
vs. 13.2%) or live birth rates (LBR) per patient (3.8% vs.
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Table 1. Comparison of patient characteristics of the LPP and standard GnRH antagonist protocol.

Age (years)

LPP group
(n = 106)

Standard GnRH antagonist
group (n = 159)

P value

38.7 ± 4.8

39 ± 3.7

NS

BMI (kg/m )

24.5 ± 3.4

23.8 ± 3.6

NS

Basal antral follicle count

4.1 ± 1.9

4.5 ± 2.1

NS

Basal FSH (mIU/mL)

12.2 ± 7.6

12.5 ± 6.1

NS

2

Duration of infertility

7.1 ± 5.7

7.8 ± 6.5

NS

Prior IVF attempts

1.7 ± 1.5

2.0 ± 2.2

NS

NS: nonsignificant
Table 2. Comparison of cycle characteristics and outcomes.
LPP group
(n = 106)

Standard GnRH antagonist
group (n = 159)

P value

Total length of stimulation (day)

11.4 ± 2.7

10.0 ± 2.7

0.01

Total dose of gonadotropin (IU)

3403.7 ± 1060.6

2984.4 ± 1112.1

0.04

Peak E2 (pg/mL)

892.5 ± 624.2

1098.0 ± 757.1

NS

Endometrial thickness on hCG day (mm)

10.9 ± 2.0

10.3 ± 1.9

NS

No. of oocytes retrieved (n)

3.5 ± 2.6

3.7 ± 2.8

NS

No. of mature oocytes (n)

2.8 ± 2.2

2.6 ± 2.2

NS

No. of normally fertilized oocytes

2.0 ± 2.1

1.7 ± 1.8

NS

Fertilization rate

65%

62%

NS

No. of embryos transferred

1.6 ± 0.6

1.7 ± 0.6

NS

Cancellation rate

9.4% (10/106)

13.2% (21/159)

NS

Implantation rate

16%

13%

NS

Clinical pregnancy rate per ET

18.8% (12/64)

22.6% (21/93)

NS

Clinical pregnancy rate per patient

11.3% (12/106)

13.2% (21/159)

NS

Live birth rate per ET

6.3% (4/64)

12.9% (12/93)

NS

Live birth rate per patient

3.8% (4/106)

9.4% (15/159)

NS

NS: Nonsignificant
ET: Embryo transfer

9.4%) and clinical pregnancy (18.8% vs. 22.6%) or live
birth rates per embryo transfer (6.3% vs. 12.9%) between
the groups.
4. Discussion
Management of PORs is a compelling issue in assisted
reproduction practice because of diverse and unclear
definitions and controversial, heterogeneous data
regarding the optimal protocol (16). To the best of our
knowledge, this is the first study based on the ESHRE
Bologna criteria and in which outcomes of a GnRH
antagonist protocol combined with luteal estradiol patch
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and GnRH antagonist pretreatment were compared with
those of a standard GnRH antagonist protocol. The results
of our study demonstrated no significant improvement in
IVF treatment outcomes in the LPP group.
In PORs, due to the effect of FSH rise during the late
luteal phase, advanced growth of fewer and more sensitive
follicles can cause asynchronism and ultimately result in
a smaller cohort available for recruitment and decreased
oocyte yield (5,18). In order to suppress FSH rise in the
preceding luteal phase, prevent asynchronous follicular
stimulation, and obtain a larger and more coordinated
cohort of follicles responding to the stimulation, oral
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contraceptive pills, microdose agonist flare protocol (MDP),
and LPP are commonly used in clinical practice (15). On
the other hand, standard GnRH antagonist protocols have
been used increasingly more often in PORs because of
their lower costs, shorter durations of stimulation, absence
of pituitary downregulation, decrease in the total amount
of gonadotropins, and at least equivalent pregnancy and
implantation rates when compared with GnRH agonist
protocols (19). Therefore, we aimed to examine whether
luteal estradiol and GnRH antagonist pretreatment could
provide additional advantages to outcomes in PORs
treated with the standard GnRH antagonist protocol. We
preferred to design a study in which we could reveal the
effect of priming treatment more accurately by comparing
LPP with the standard GnRH antagonist protocol instead
of MDP, which was the control protocol in most studies
(7,11,12,14,15)
Our findings are consistent with earlier studies
demonstrating similar numbers of oocytes retrieved in the
LPP group when compared with controls (7,11,12,14,15).
A recent and single randomized study assessing IVF
outcomes in 54 poor responders undergoing a MDP or
a LPP showed no significant differences in number of
oocytes retrieved, cancellation rates, or pregnancy rates
between the two protocols (14). Ata et al. compared 57
anticipated poor responders who underwent LPP or MDP
retrospectively and showed that oocyte yield and pregnancy
outcomes were similar in the two groups (12). Previously,
a retrospective study in which 45 poor responders using
LPP were compared with 76 patients using MDP showed
similar number of oocytes retrieved, cancellation rates, or
pregnancy rates (15). In a recent retrospective study that
compared the IVF outcomes of luteal estrogen priming and
letrozole co-treatment in an antagonist protocol in PORs
according to the Bologna criteria revealed no significant
difference in terms of pregnancy outcome (20). Recently,
a meta-analysis determined that there was no significant
improvement in the number of oocytes retrieved in
PORs treated with luteal estradiol priming protocols (16).
Furthermore, it was shown that initiation of FSH in the
luteal phase yielded similar retrieved oocyte number
and pregnancy rates as compared to initiation of FSH in
the follicular phase in two studies (21,22). These results
suggest that in fact follicular recruitment has already been
initiated before the last menstrual luteal phase and so the
pretreatment can synchronize the follicles but cannot
improve oocyte yield (23). However, in two other studies
luteal phase priming treatment improved ovarian response
to ovarian hyperstimulation (10,13). Dragisic et al.
investigated the effect of the luteal estradiol patch/GnRH
antagonist protocol by comparing the outcomes with
previous cycles of the same patients without LPP. They
reported a significantly lower cancellation rate, a higher

mean number of oocytes retrieved and fertilized, and a
higher mean number of embryos transferred in the LPP
group (10). The heterogeneity of the previous treatment
protocols used in comparison might yield inconclusive
results. Chang et al. examined PORs undergoing
stimulation with the luteal estradiol protocol and standard
GnRH antagonist protocol retrospectively and found
that the luteal estradiol protocol had significantly higher
peak estradiol levels, numbers of oocytes retrieved, and
pregnancy rates and lower cancellation rates (13). These
results may be the consequence of heterogeneity in the
luteal estradiol group in which most of the patients had
used estradiol through the day of hCG administration. It
is known that estrogen induces FSH receptor proliferation
in granulosa cells and stimulates follicular growth and
granulosa cell proliferation. Extended use of estradiol can
cause higher peak estradiol levels and numbers of oocytes
retrieved.
The successful outcomes in PORs were closely linked
to increased numbers of retrieved oocytes and transferred
embryos (24,25). In relation to this, we could not determine
any statistically significant differences between the two
groups in terms of cycle cancellation rate or LBR. In the
current literature, the only study in which the primary
outcome was LBR, similar to ours, demonstrated that
estradiol priming protocol did not improve IVF outcomes
(7). Our results also showed a significant increase in the
total dose of gonadotropins and duration of stimulation in
the LPP group as reported in many other trials (7,11–13).
Peak E2 level was lower in the LPP than in the standard
GnRH antagonist protocol most probably due to dual
suppression with antagonist and estradiol in the late luteal
phase. Suppression of FSH in the preceding luteal phase
and synchronic antral follicles small in diameter at the
beginning of stimulation may be the reason for the increase
in the total dose of gonadotropins and days of stimulation
(7,13). Although the higher gonadotropin doses were
used in the LPP group in our study, this situation did not
improve cycle outcomes as it has been demonstrated in the
literature (26–28).
The limitations of this study are its retrospective
design and small sample size as with most published trials
in which luteal estradiol priming protocol was compared
with other protocols in poor responders. Despite these
limitations, comparison of two protocols that differ only
in the pretreatment component gave us an advantage to
demonstrate the impact of luteal estradiol and antagonist
pretreatment on IVF outcomes more precisely.
In conclusion, the luteal phase estradiol/GnRH
antagonist priming protocol does not improve IVF
outcomes compared with the standard GnRH antagonist
protocol in PORs. Concerning the issue of costeffectiveness, adding luteal phase estradiol and GnRH
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antagonist pretreatment to GnRH antagonist protocols
seems to increase the cost of the COH cycle, which results
in an additional financial burden for poor responders,

who generally participate in multiple trials. Ultimately,
randomized controlled trials with larger sample sizes are
required.
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